Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 528

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Effect of Online Hemodiafiltration on All-Cause Mortality and Cardiovascular Outcomes

Open access
Grooteman, Muriel P.C., van den Dorpel, Marinus A., Bots, Michiel L., Penne, E. Lars, van der Weerd, Neelke C., Mazairac, Albert H.A., den Hoedt, Claire H., van der Tweel, Ingeborg, Lévesque, Renée, Nubé, Menso J., ter Wee, Piet M., Blankestijn, Peter J. · 2012 · Journal of the American Society of Nephrology

Abstract

In patients with ESRD, the effects of online hemodiafiltration on all-cause mortality and cardiovascular events are unclear. In this prospective study, we randomly assigned 714 chronic hemodialysis patients to online postdilution hemodiafiltration (n=358) or to continue low-flux hemodialysis (n=356). The primary outcome measure was all-cause mortality. The main secondary endpoint was a composite of major cardiovascular events, including death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, therapeutic coronary intervention, therapeutic carotid intervention, vascular intervention, or amputation. After a mean 3.0 years of follow-up (range, 0.4-6.6 years), we did not detect a significant difference between treatment groups with regard to all-cause mortality (121 versus 127 deaths per 1000 person-years in the online hemodiafiltration and low-flux hemodialysis groups, respectively; hazard ratio, 0.95; 95% confidence interval, 0.75-1.20). The incidences of cardiovascular events were 127 and 116 per 1000 person-years, respectively (hazard ratio, 1.07; 95% confidence interval, 0.83-1.39). Receiving high-volume hemodiafiltration during the trial associated with lower all-cause mortality, a finding that persisted after adjusting for potential confounders and dialysis facility. In conclusion, this trial did not detect a beneficial effect of hemodiafiltration on all-cause mortality and cardiovascular events compared with low-flux hemodialysis. On-treatment analysis suggests the possibility of a survival benefit among patients who receive high-volume hemodiafiltration, although this subgroup finding requires confirmation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2011121140

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 528

Metadata

Authors
Grooteman, M. P. C., van den Dorpel, M. A., Bots, M. L., Penne, E. L., van der Weerd, N. C., Mazairac, A. H. A., den Hoedt, C. H., van der Tweel, I., Lévesque, R., Nubé, M. J., ter Wee, P. M., & Blankestijn, P. J.
Venue
Journal of the American Society of Nephrology
Published
2012-06
Volume
23
Issue
6
Pages
1087-1096
ISSN
1046-6673 (ISSN-L)
OpenAlex
W2136929928
Cited by
528
References
12
FWCI
41.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Online Hemodiafiltration on All-Cause Mortality and Cardiovascular Outcomes. https://app.cochat.ai/papers/10.1681/asn.2011121140
The paper
Grooteman, M. P. C., van den Dorpel, M. A., Bots, M. L., Penne, E. L., van der Weerd, N. C., Mazairac, A. H. A., den Hoedt, C. H., van der Tweel, I., Lévesque, R., Nubé, M. J., ter Wee, P. M., & Blankestijn, P. J. (2012). Effect of Online Hemodiafiltration on All-Cause Mortality and Cardiovascular Outcomes. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2011121140

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.